Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1900872 | 0.90 | SUV39H2 (0.48) | MAPTALDH1A1LMNAUSP30NR1H2 | |
| SCHEMBL1904867 | 0.90 | SUV39H2 (0.48) | MAPTALDH1A1LMNAUSP30NR1H2 | |
| SCHEMBL1900868 | 0.90 | SUV39H2 (0.48) | MAPTALDH1A1LMNAUSP30NR1H2 | |
| SCHEMBL13419734 | 0.87 | MAPT (0.55) | MAPTALDH1A1LMNAUSP30NR1H2 | |
| SCHEMBL16824991 | 0.87 | MAPT (0.55) | MAPTALDH1A1LMNAUSP30NR1H2 | |
| SCHEMBL1902481 | 0.85 | MAPT (0.48) | MAPTALDH1A1LMNAMAP4K4SUV39H2 | |
| SCHEMBL29767485 | 0.84 | CHRM4 (0.53) | MAPTALDH1A1LMNAMAP4K4GPR119 | |
| SCHEMBL13419658 | 0.83 | MAPT (0.76) | MAPTALDH1A1LMNAMAP4K4GPR119 | |
| SCHEMBL18186321 | 0.83 | MAPT (0.76) | MAPTALDH1A1LMNAMAP4K4GPR119 | |
| SCHEMBL30591201 | 0.82 | CYP3A4 (0.56) | MAPTALDH1A1LMNAUSP30GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851084-B2 | Piperazine derivatives as TRPML modulators | Lysoway Therapeutics, Inc. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190248764-A1 | PIPERAZINE DERIVATIVES AS TRPML MODULATORS | CalyGene Biotechnolgy, Inc. (US) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851084-B2 | Piperazine derivatives as TRPML modulators | TRPM5, TRPM2, TRPM4 | MAPT 577/4885ALDH1A1 2820/4885LMNA 760/4885 |
| US-20190248764-A1 | PIPERAZINE DERIVATIVES AS TRPML MODULATORS | TRPM5, TRPM2, TRPM4 | MAPT 577/4885ALDH1A1 2820/4885LMNA 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.